Mayne Pharma Agrees to $604m Takeover Proposal from Gedeon Richter

Mayne Pharma Agrees to $604m Takeover Proposal from Gedeon Richter

Mayne Pharma agrees to Gedeon Richter’s $604m cash takeover at $6.40 a share—a 99.4% premium—with unanimous board backing.

Nik Hill
Nik HillJournalist
· 2 min read
In this storyMYX
In briefAt-a-glance3 takeaways
  • 01Richter offers $604m cash at $6.40/share, a 99.4% premium.
  • 02Board and 22.14% of shareholders support the deal.
  • 03Sale and approvals required; March 2027 close targeted.

Mayne Pharma (ASX: MYX) has agreed to a $604 million cash takeover by Hungarian pharmaceutical group Gedeon Richter under a scheme of arrangement offering shareholders $6.40 per share.

The proposed acquisition represents a 99.4% premium to Mayne Pharma’s closing share price on 16 November and would transfer full ownership to a new Australian subsidiary of Richter.

The cash consideration also stands 124% above the 30-day volume-weighted average price, 122% above the 90-day VWAP, and 145% above the 180-day VWAP.

Mayne Pharma’s board unanimously supports the transaction, provided no superior proposal emerges and an independent expert concludes and continues to conclude that it is in shareholders’ best interests.

Richter operates in around 50 countries and views Mayne Pharma’s US commercial presence and product portfolio as a foundation for expanding its women’s health activities.

Advertisement

International Sale Condition

The takeover depends on Mayne Pharma completing its previously agreed sale of the International business segment to Evaris Pharma, a transaction disclosed on 6 November.

That divestment requires Australian Competition and Consumer Commission approval, while the proposed Richter acquisition separately requires clearance from the Foreign Investment Review Board.

The acquisition must also satisfy US antitrust requirements, obtain shareholder and court approvals, and avoid specified adverse changes or other events that could prevent completion.

Richter intends to finance the acquisition entirely from internal cash resources, leaving the scheme without a financing condition.

The $604m equity valuation assumes approximately 94.4 million shares, including relevant equity incentives and conversion of Mayne Pharma’s notes maturing on 31 December 2026.

Advertisement

Major Shareholder Support

The three largest shareholders—Funicular Funds, Bruce Mathieson and Trium Capital—have indicated support for the transaction in the absence of a superior proposal.

Together they hold 22.14% of Mayne Pharma’s ordinary shares, with respective interests of 9.82%, 6.46%, and 5.85%.

“The Board’s priority throughout has been to maximise value and certainty for all shareholders,” chair Bruce Robinson said.

“Together with the recent binding agreement to sell our International business to Evaris Pharma, the Scheme delivers on that priority.”

Mayne Pharma has been concentrating on its US Women’s Health and Dermatology businesses, including its DistributeRx platform launched in March 2026.

Advertisement

March Completion Targeted

Shareholders are expected to receive a scheme booklet and independent expert’s assessment in mid-December, following an initial court hearing.

The shareholder vote is provisionally scheduled for late January 2027, with the second court hearing and implementation targeted for mid-to-late March 2027.

These dates remain indicative and depend on the required approvals and satisfaction or waiver of the applicable scheme conditions.

Under the transaction terms, Mayne Pharma is subject to exclusivity restrictions and Richter holds matching rights over qualifying competing proposals, subject to fiduciary exceptions.

The agreement also provides for a $6m break fee and a corresponding reverse break fee in specified circumstances.

Subscribe · daily wire

Get the wire before the market opens.

The ASX small-cap stories that matter, filed before 9am AEST. Curated by the Small Caps desk.

Join 100,000+ investors. Unsubscribe anytime.
Nik Hill
About the author

Nik Hill

Journalist
View all articles

More like this

View all latest